Skip to Main Content

Pharmaceutical manufacturing has had to navigate transformational changes during the pandemic, just like many other industrial sectors. Demand for manufacturing capacity reached levels that would have been unthinkable a few short years ago.

Yet although the situation was unprecedented, and the measures taken extraordinary, the pandemic did not actually change the direction of travel for how biopharma companies manufacture drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment